文献速递类风湿关节炎其他结缔组织病

2型糖尿病、血糖控制及相关治疗与类风湿关节炎风险:回顾性队列研究

Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

结果显示2型糖尿病组类风湿关节炎风险降低(aHR 0.73,95%CI 0.67–0.79),此降低可能归因于他汀类药物使用;血糖控制及二甲双胍、DPP-4抑制剂使用与类风湿关节炎发生无关。

要点

  • 2型糖尿病患者类风湿关节炎发病风险降低,aHR为0.73(95%CI 0.67–0.79)。
  • 他汀类药物对2型糖尿病患者类风湿关节炎进展有保护作用,aHR 0.76(95%CI 0.66–0.88),呈持续时间-效应关系。
  • 血糖控制、二甲双胍及DPP-4抑制剂使用与类风湿关节炎发生无显著关联。

核心结论

  • 2型糖尿病患者类风湿关节炎风险降低,可能归因于他汀类药物的使用。

主要发现

  • 在从未使用他汀类药物的患者中,aHR为0.89(95%CI 0.69–1.14)。
  • 时变分析显示,血糖控制[aHR 1.00(95%CI 0.99–1.00)]、二甲双胍使用[aHR 1.00(95%CI 0.82–1.22)]及DPP-4抑制剂使用[aHR 0.94(95%CI 0.71–1.24)]与类风湿关节炎发生无关联。
  • 他汀类药物对2型糖尿病患者类风湿关节炎进展显示保护效应[aHR 0.76(95%CI 0.66–0.88)],且存在持续时间-效应关系的证据。

临床怎么用

  • 对于2型糖尿病患者,他汀类药物的使用可能与较低的类风湿关节炎风险相关,临床决策时可综合考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the incident risk of RA in patients with type 2 diabetes mellitus (T2DM) and to explore the role of glycaemic control and associated therapeutic use in the onset of RA. METHODS: This study was a retrospective cohort study using patients derived from the IQVIA Medical Research Data (IMRD-UK) database between 1995 and 2019. A total of 224 551 newly diagnosed patients with T2DM were matched to 449 101 patients without T2DM and followed up to assess their risk of RA. Further analyses investigated the effect of glycaemic control, statin use and anti-diabetic drugs on the relationship between T2DM and RA using a time-dependent Cox regression model. RESULTS: During the study period, the incidence of RA was 8.1 and 10.6 per 10 000 person-years in the exposed and unexposed groups, respectively. The adjusted hazard ratio (aHR) was 0.73 (95% CI 0.67, 0.79). In patients who had not used statins in their lifetime, the aHR was 0.89 (95% CI 0.69, 1.14). When quantifying the effects of glycaemic control, anti-diabetic drugs and statins using time-varying analyses, there was no association with glycaemic control [aHR 1.00 (95% CI 0.99, 1.00)], use of metformin [aHR 1.00 (95% CI 0.82, 1.22)], dipeptidyl peptidase-4 inhibitors [DPP4is; aHR 0.94 (95% CI 0.71, 1.24)] and the development of RA. However, statins demonstrated a protective effect for progression of RA in those with T2DM [aHR 0.76 (95% CI 0.66, 0.88)], with evidence of a duration-response relationship. CONCLUSION: There is a reduced risk of RA in patients with T2DM that may be attributable to the use of statins.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Zemedikun DT, Gokhale K, Chandan JS, et al. Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study. Rheumatology (Oxford). 2021. PMID: 33590842. doi:10.1093/rheumatology/keab148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。